-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is a hematopoietic malignancy characterized by clonal proliferation of plasma cel.
Multiple myeloma (MM) is a hematopoietic malignancy characterized by clonal proliferation of plasma cel.
After HDS269B infusion (9×106 CAR+ cells/kg), 17 patients (369%, 11 ECOG 0-2, 6 ECOG 3-4) developed cytokine release syndrome [Grade 1-2: 14 patients ( 257%); Grade 3: 3 patients (12%.
Table: Adverse Events (AEs) in 49 Patients Treated with Anti-bcma CAR-T Cells
Table: Adverse Events (AEs) in 49 Patients Treated with Anti-bcma CAR-T CellsMedian progression-free survival (PFS) and overall survival (OS) were 10 months (95% CI 3–17) and 29 months (95% CI 10–40), respective.
Median progression-free survival (PFS) and overall survival (OS) were 10 months (95% CI 3–17) and 29 months (95% CI 10–40), respective.
Figure: Survival of RRMM patients infused with BCMA CAR-T cel.
Figure: Survival of RRMM patients infused with BCMA CAR-T cel.
The study showed that the safety and efficacy of HDS269B were comparable to other CAR-t therapies evaluated in previous tria.
Overall, single-cell sequencing indicated that the therapeutic effect may be related to mTORC1 signali.
Original source:
Original source:Du, J ,Wei, R ,Jiang, S , et .
Du, J ,Wei, R ,Jiang, S , et .
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance statu.
Am J Hemato.
2022 ;1 -
doi:11002/a.
2658 Du, J ,Wei, R ,Jiang, S , et .
CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance statu.
Am J Hemato.
2022 ; 1- doi:11002/a.
2658 Du, J Wei, R Jiang, S CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status Am J Hematol 2022 1 9in this message
